flu

  • Agilent Technologies introduces commercial hybrid supercritical fluid/UHPLC system

    The 1260 Infinity Hybrid SFC/UHPLC system delivers LC-like sensitivity over the UHPLC power range.

    flu | 03 April 2012

  • BiondVax’s universal flu vaccine improves existing flu vaccines in elderly

    BiondVax Pharmaceuticals announced positive results from its second Phase II clinical trial (BVX-005) of the Universal Influenza Vaccine (Multimeric-001) developed by Biondvax for improving existing flu vaccines in elderly.

    flu | 20 February 2012

  • A*STAR SIMTech launches microfluidics foundry

    Aims to exploit opportunities in the microfluidics space through harnessing its strengths in multi-disciplinary research across the biomedical, physical and engineering sciences.

    flu | 21 September 2011

  • Novartis supports influenza framework at World Health Assembly

    Novartis welcomes the decision to endorse the Pandemic Influenza Preparedness Framework (PIP Framework) at the sixty-fourth World Health Assembly. The PIP Framework sets out the roles and commitments of different stakeholders, including the World Hea…

    flu | 19 May 2011

  • Immunization begins for universal flu vaccine phase 2a

    BiondVax begun to immunize subjects in a phase 2a clinical trial of the multimeric-001 universal flu vaccine candidate. The study will evaluate the safety and immunogenicity of the Multimeric-001 vaccine. The vaccine comprised a unique, propriet…

    flu | 31 October 2010

  • Phase two clinical trial for universal influenza vaccine

    BiondVax Pharmaceuticals announces that it has received the approvals of the Ethics (“Helsinki”) Committees of the Institutional Review Boards (IRB) of both the Hadassah Clinical Research Center at Hadassah University Hospital in Jerusalem (Hada…

    flu | 08 September 2010

  • Award for work on universal influenza vaccine

    Frost & Sullivan announces the award of its 2010 European Influenza Vaccines Technology Innovation Award to BiondVax Pharmaceuticals for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provi…

    flu | 02 August 2010

  • Potential supply of influenza vaccine for Southeast Asia

    Cytos Biotechnology and Agency for Science, Technology and Research (A*STAR) announce their first collaboration on a virus-like particle (VLP) vaccine. This partnership, which involves academic and clinical partners across Singapore, aims at res…

    flu | 22 July 2010

  • Marketing clearance for Heparin Lock Flush Solution, USP

    APP Pharmaceuticals announced that it has received clearance from the US FDA to market preservative-free Heparin Lock Flush Solution, USP in two dosage strengths, 10 USP Units/1 mL and 100 USP Units/1 mL, and will soon launch these single dose vial …

    flu | 09 July 2010

  • Rare anti-influenza antibodies

    Scientists have identified a new, highly conserved molecular target on the influenza A virus and demonstrated that human antibodies against this target are protective in animal models of seasonal and highly-pathogenic avian influenza. The work wa…

    flu | 01 July 2010

Page 1 Next > Last >>